TIDMABC

RNS Number : 5520A

ABCAM PLC

02 June 2021

2 June 2021

ABCAM PLC

("Abcam" or "the Company")

Change of accounting reference date and publication of Shareholder Circular and Notice of General Meeting

Cambridge, UK: Abcam plc (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, confirms that further to its announcement on 8 March regarding its intention to change its year end, the Board has now formally approved the change of the Company's accounting reference date and financial year end from 30 June to 31 December.

As a result, the Company's next three financial reporting events will be as follows:

-- Unaudited results for the six- and twelve-month periods to 30 June 2021 to be announced before 30 September 2021;

-- Audited results for the twelve- and 18-month periods to 31 December 2021 to be announced before 31 March 2022;

   --      Publication of the 2021 annual report and accounts expected before the end of April 2022.

The Company will also release a short pre-close trading update on the day of the forthcoming General Meeting, details of which are set out below.

Publication of Shareholder Circular and Notice of General Meeting

Abcam also announces that it will publish and post (or otherwise make available) to shareholders a Circular (the "Circular") containing a Notice of General Meeting at which a resolution will be proposed to approve a new Profitable Growth Incentive Plan. Resolutions will also be proposed to approve a revised Remuneration Policy which incorporates amendments to the Company's current Remuneration Policy to reflect the new Profitable Growth Incentive Plan, and to renew authorities to allot shares and disapply pre-emption rights that would otherwise expire before the next Annual General Meeting, intended to be held in spring 2022.

The General Meeting will be held on 1 July 2021 at 2.00 pm at the Company's registered office at Discovery Drive, Cambridge Biomedical Campus, Cambridge, CB2 0AX.

A copy of the Circular and Notice of General Meeting has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism .

The Circular and Notice of General Meeting will be posted tomorrow, 3 June 2021, to those shareholders that have elected to receive paper communications. Shareholders that have not elected to receive paper communications will be notified of the availability of these documents on the investor section of Abcam plc's corporate website, corporate.abcam.com/investors .

For further information, please contact:

 
Abcam                                                  + 44 (0) 1223 696 000 
Marc Perkins, Company Secretary 
 James Staveley, Vice President, Investor Relations 
 
  Numis - Nominated Advisor & Joint Corporate Broker   + 44 (0) 20 7260 1000 
Garry Levin / Freddie Barnfield / Duncan Monteith 
 
  Morgan Stanley - Joint Corporate Broker              + 44 (0) 207 425 8000 
Tom Perry / Luka Kezic 
 
 
  J.P. Morgan Cazenove - Joint Corporate Broker        + 44 (0) 20 7742 4000 
James Mitford / Hemant Kapoor 
 
  FTI Consulting                                       + 44 (0) 20 3727 1000 
Ben Atwell / Natalie Garland-Collins

About Abcam plc

As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated antibodies and assays to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.

In the fiscal year ended 30 June 2020, Abcam's worldwide customer base consisted of approximately 750,000 life science researchers. By actively listening to and collaborating with these researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

Founded in 1998 and headquartered in Cambridge, UK, the Company has served customers in more than 130 countries. Abcam's ordinary shares were admitted to trading on AIM in 2005 (AIM: ABC) and its American Depositary Shares began trading on the Nasdaq Global Market in October 2020 (Nasdaq: ABCM).

Please visit corporate.abcam.com to find out more.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOGFIFIDRDIFIIL

(END) Dow Jones Newswires

June 02, 2021 03:30 ET (07:30 GMT)

Abcam (LSE:ABC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Abcam Charts.
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Abcam Charts.